

SEQUENCE LISTING

<110> Focke, Margarete
Mahler, Vera
Sperr, Wolfgang R.
Valent, Peter
Kraft, Dietrich
Valenta, Rudolf

<120> Allergy Vaccines and Their Preparation

<130> 0273-0005

<140>

<141> 2001-12-27

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: solvent-exposed peptide

<400> 1

Met Gly Val Phe Asn Tyr Glu Thr Glu Thr Thr Ser Val Ile Pro Ala 1 5 10 15

Ala Arg Leu Phe Lys Ala Phe Ile Cys 20

<210> 2

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 solvent-exposed peptide

<400> 2

Leu Phe Pro Lys Val Ala Pro Gln Ala Ile Ser Ser Val Glu Asn Ile
1 5 10 15

Glu Gly Asn Gly Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Cys
20 25 30

<210> 3

<211> 31

<212> PRT

```
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      solvent-exposed peptide
<400> 3
Cys Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Pro Glu Gly Phe Pro
Phe Lys Tyr Val Lys Asp Arg Val Asp Glu Val Asp His Thr Asn
                                  25
             20
<210> 4
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
solvent-exposed peptide
[]
≰400> 4
Asp Gly Gly Ser Ile Leu Lys Ile Ser Asn Lys Tyr His Thr Lys Gly
Asp His Glu Val Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Cys
                                  25
14
≰210> 5
×211> 32
| 2212> PRT
| 2213> Artificial Sequence
€220>
223> Description of Artificial Sequence:
      solvent-exposed peptide
<400> 5
Cys Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu Thr Leu
                   5
Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn
                                  25
              20
<210> 6
<211> 31
<212> PRT
<213> Artificial Sequence
 <220>
```

Gly Pro Ile Gly Asp Thr Leu Glu Lys Ile Ser Asn Glu Ile Lys
20 25 30

SEQUENCE LISTING

```
<110> Focke, Margarete
      Mahler, Vera
      Sperr, Wolfgang R.
      Valent, Peter
      Kraft, Dietrich
      Valenta, Rudolf
<120> Allergy Vaccines and Their Preparation
<130> 0273-0005
<140>
<141> 2001-12-27
<160> 6
<170> PatentIn Ver. 2.1
<210> 1
≩211> 25
≹212> PRT
名13> Artificial Sequence
(1)
<220>
223> Description of Artificial Sequence:
      solvent-exposed peptide
å≟
₹400> 1
Met Gly Val Phe Asn Tyr Glu Thr Glu Thr Thr Ser Val Ile Pro Ala
. 1
Ala Arg Leu Phe Lys Ala Phe Ile Cys
             20 ,
١,
Ü
210> 2
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
      solvent-exposed peptide
Leu Phe Pro Lys Val Ala Pro Gln Ala Ile Ser Ser Val Glu Asn Ile
Glu Gly Asn Gly Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Cys
                                 25
<210> 3
<211> 31
```

<212> PRT

```
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:
   solvent-exposed peptide
<400> 3
Cys Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Pro Glu Gly Phe Pro
                                       10
Phe Lys Tyr Val Lys Asp Arg Val Asp Glu Val Asp His Thr Asn
                                   25
             20
<210> 4
<211> 31
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:
solvent-exposed peptide
₹<del>4</del>00> 4
isp Gly Gly Ser Ile Leu Lys Ile Ser Asn Lys Tyr His Thr Lys Gly
(1)
Asp His Glu Val Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Cys
                                   25
14
<u>k</u>210> 5
$211> 32
$212> PRT
$213> Artificial Sequence
₹220>
🚧 23> Description of Artificial Sequence:
      solvent-exposed peptide
<400> 5
Cys Lys Ala Glu Gln Val Lys Ala Ser Lys Glu Met Gly Glu Thr Leu
                   5
                                       10
Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn
                                   25
             20
<210> 6
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
```

Gly Pro Ile Gly Asp Thr Leu Glu Lys Ile Ser Asn Glu Ile Lys 20 25 30